ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 048,89
-0,20%
Dow Jones
38 386,09
0,38%
DAX
18 050,54
-0,45%
Brent Oil
87,465
0,21%
Bitcoin
62 138,60
-2,66%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Halozyme Therapeutics Incorporated (HALO)

  7. Halozyme Therapeutics Incorporated (HALO) Actualités

HALO Halozyme Therapeutics Incorporated

38,77
0,00 (0,00%)
Avant marché
Dernière mise à jour : 10:00:54
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Halozyme Therapeutics Incorporated HALO NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 38,77 10:00:54
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
38,77
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
25/4/202422:45PRNUSMahesh Krishnan Elected to Halozyme's Board of Directors
23/4/202414:30PRNUSHalozyme to Report First Quarter 2024 Financial and..
04/3/202422:13EDGAR2Form PRE 14A - Other preliminary proxy statements
29/2/202400:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202422:07EDGAR2Form 144 - Report of proposed sale of securities
27/2/202423:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202423:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202422:08EDGAR2Form 144 - Report of proposed sale of securities
27/2/202414:30PRNUSHalozyme to Participate in Upcoming Investor Conferences
21/2/202400:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202400:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202400:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202400:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202422:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
20/2/202422:03EDGAR2Form 8-K - Current report
20/2/202422:01PRNUSHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL..
16/2/202423:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202412:19EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202422:30PRNUSHalozyme To Report Fourth Quarter and Full Year 2023..
29/1/202422:15PRNUSHalozyme Announces Takeda Received European Commission..
23/1/202417:52EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
18/1/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202414:30PRNUSHalozyme Announces argenx Received Approval in Japan for..
17/1/202422:56EDGAR2Form 144 - Report of proposed sale of securities
17/1/202414:10EDGAR2Form 8-K - Current report
16/1/202422:26EDGAR2Form 144 - Report of proposed sale of securities
16/1/202414:15PRNUSHalozyme Announces Takeda Receives FDA Approval for HYQVIA®..
16/1/202407:15PRNUSHalozyme Announces Roche Receives European Commission..
12/1/202415:25PRNUSHalozyme to Host Investor Business Forum and Long-Term..
05/1/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/12/202301:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202322:40EDGAR2Form 144 - Report of proposed sale of securities
12/12/202322:21EDGAR2Form 144 - Report of proposed sale of securities
27/11/202314:00PRNUSHalozyme to Present at Upcoming Investor Conferences
16/11/202322:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202315:00PRNUSHalozyme Announces argenx Receives European Commission..
15/11/202322:17EDGAR2Form 144 - Report of proposed sale of securities
14/11/202322:19EDGAR2Form 144 - Report of proposed sale of securities
06/11/202322:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202322:04EDGAR2Form 8-K - Current report
06/11/202322:01PRNUSHALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING..
06/11/202313:30PRNUSHalozyme and Acumen Pharmaceuticals Enter Global..
30/10/202323:35PRNUSHalozyme To Report Third Quarter 2023 Financial and..
19/10/202313:15PRNUSPositive Topline Results Reported from Bristol Myers..

Dernières Valeurs Consultées

NASDAQ
HALO
Halozyme Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés